What is Grand Pharmaceutical Group Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Grand Pharmaceutical Group's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Enterprise Value falls into.
Grand Pharmaceutical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Grand Pharmaceutical Group's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (FRA:MX6A) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Grand Pharmaceutical Group's EV-to-EBIT for today is
Grand Pharmaceutical Group's current Enterprise Value is €2,518 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €365 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Grand Pharmaceutical Group's EV-to-EBITDA for today is:
Grand Pharmaceutical Group's current Enterprise Value is €2,518 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was €365 Mil.
Grand Pharmaceutical Group's current Enterprise Value is €2,518 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €1,407 Mil.
Grand Pharmaceutical Group's current Enterprise Value is €2,518 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Grand Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €157 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group Enterprise Value Related Terms
Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Grand Pharmaceutical Group Ltd, is an international pharmaceutical company of technological innovation. Its core businesses cover three areas: nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision interventional diagnosis and treatment technology, pharmaceutical technology, and biotechnology. Based on the pharmaceutical and biological industries, the Group focuses on the needs of patients, and technological innovation as the driving force Geographically, it derives a majority of its revenue from the PRC and also has a presence in America; Europe; and Asia other than the PRC, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:MX6A has been successfully added to your 